CBO warns of almost 60 fewer new drugs over three decades with Medicare drug negotiations bill

As drug pricing legislation begins to gain steam on Capitol Hill moving into the fall, the Congressional Budget Office is offering an updated look at the effects that House Speaker Nancy Pelosi’s drug pricing bill, known as HR 3, would have in chilling biopharma R&D over 30 years.